Abstract
Clinical quality metrics have become ubiquitous in modern health care. The primary goal is to improve patient care delivery and overall outcomes, but they have also been tied to reimbursement and general quality improvement efforts. Numerous organizations have developed and/or promoted the use of quality metrics, including many for oncology. Ultimately, the hope is that increased use of well-conceived quality metrics will lead to improved survival. This chapter outlines the approach taken by the American College of Surgeons Commission on Cancer (CoC), and highlights recent data on the relationship between quality measures and improvements in survival.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
American College of Surgeons: Commission on Cancer. https://www.facs.org/quality-programs/cancer/coc. Accessed 6 Feb 2018.
American College of Surgeons: Commission on Cancer, National Cancer Database, CoC Quality of Care Measures. https://www.facs.org/quality-programs/cancer/ncdb/qualitymeasures. Accessed 6 Feb 2018.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomized trials. Lancet. 2011;378(9804):1707–16.
Hassett MJ, Hughes ME, Niland JC, et al. Selecting high priority quality measures for breast cancer quality improvement. Med Care. 2008;46:762–70.
Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus Tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351:971–7.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analysis of long-term outcome among 100,000 women in 123 randomized trials. Lancet. 2012;379(9814):432–44.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Clarke M, Coates AS, Darby SC, et al. Adjuvant chemotherapy in estrogen-receptor-poor breast cancer: patient level meta-analysis of randomized trials. Lancet. 2008;371(9606):29–40.
Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365(9472):1687–717.
National Quality Forum: 0559 Combination chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or Stage IB-III hormone receptor negative breast cancer. http://www.qualityforum.org/QPS/QPSTool.aspx. Accessed 6 Feb 2018.
National Quality Forum: 0220 Adjuvant hormonal therapy. http://www.qualityforum.org/QPS/QPSTool.aspx. Accessed 6 Feb 2018.
National Quality Forum: 0223 Adjuvant chemotherapy is recommended within 4 months (120 days) of diagnosis to patients under the age of 80 with AJCC III (lymph node positive) colon cancer. http://qualityforum.org/QPS/QPSTool.aspx. Accessed 6 Feb 2018.
National Quality Forum: 0225 At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer. http://qualityforum.org/QPS/QPSTool.aspx. Accessed 6 Feb 2018.
Ludwig MS, Goodman M, Miller DL, Johnstone PA. Postoperative survival and the number of lymph nodes sampled during resection of node-negative non-small cell lung cancer. Chest. 2005;128(3):1545–50. http://www.ncbi.nlm.nih.gov/pubmed/16162756.
Limited thoracic lymphadenectomy worsens survival in 55,122 patients with resected Stage I non-small cell lung cancer P217 society of surgical oncology 66th Annual Symposium, March 6–9, 2013.
Samayoa AX, Pezzi TA, Pezzi CM, et al. Rationale for a minimum number of lymph nodes removed with non-small cell lung cancer resection: correlating the number of nodes removed with survival in 98,970 patients. Ann Surg Oncol. 2016;23(Suppl 5):1005–11.
Handy JR Jr, Costas K, Nisco S, et al. Regarding American College of Surgeons Commission on cancer non-small cell lung cancer quality measure 10RLN. Ann Thorac Surg. 2016;102:1040–1.
Krantz SB, Lutfi W, Kuchta K, et al. Improved lymph node staging in early-stage lung cancer in the National Cancer Database. Ann Thorac Surg. 2017;104:1805–14.
Smeltzer MP, Faris NR, Ray MA, et al. Association of pathologic nodal staging quality with survival among patients with non-small cell lung cancer after resection with curative intent. JAMA Oncol. 2018;4(1):80–7.
Non-small cell lung cancer Version 2.2018. In: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). http://www.nccn.org. Accessed 8 Feb 2018.
Shulman LN, Palis BE, McCabe R, et al. Survival as a quality metric of cancer care: use of the National Cancer Data Base to assess hospital performance. J Oncol Pract. 2018;14(1):e59–72.
Cancer program standards: ensuring patient-centered care manual. 2016 ed. https://www.facs.org/quality-programs/cancer/coc/standards. Accessed 8 Feb 2018.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Facktor, M.A. (2018). The Role of Quality Metrics in Improving Oncologic Survival. In: Hopewood, P., Milroy, M. (eds) Quality Cancer Care . Springer, Cham. https://doi.org/10.1007/978-3-319-78649-0_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-78649-0_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-78648-3
Online ISBN: 978-3-319-78649-0
eBook Packages: MedicineMedicine (R0)